<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 am</td>
<td>Opening and Welcome</td>
<td>Jennifer Dill, CCRP, CRP Committee Chair</td>
</tr>
</tbody>
</table>
| 8:05 am | S1400 Master Lung Protocol, “Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer | Vassiliki A. Papadimitrakopoulou, MD Professor of Medicine  
Department of Thoracic/HN Medical Oncology  
Jay and Lori Eisenberg Endowed Professor  
MD Anderson Cancer Center, Houston, TX |
| 9:05 am | (ALCHEMIST) -Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials  
A151216–Screening Component  
A081105-EGFR Treatment Component  
E4512-ALK Treatment Component | Olwen Hahn, MD  
Assistant Professor  
Section of Hematology-Oncology  
University of Chicago  
Executive Officer, Alliance for Clinical Trials in Oncology |
| 10:05 am | BREAK                                                                                          |                                                                                             |
| 10:20 am | A071101 A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96)(NSC #725085, Alliance IND#15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM) | Andrew Parsa, MD  
UCSF Mt Zion  
Parisa Mirzadehgan, MPH, CCRP  
Cedars-Sinai Medical Center |
| 11:20 am | The Clinical Trial Assessment of Infrastructure Matrix Tool (CT AIM) to Improve the Quality of Research Conduct in the Community | Kandie Dempsey, MS, RN, OCN  
Delaware/Christiana Care NCI Community Oncology Research Program (NCORP) |
| 12 pm  | Evaluations/Closure                                                                            |                                                                                             |

***CE CREDIT SESSIONS MARKED IN BLUE***